Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909305 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53SMN1; SMN2 | |
| SCHEMBL11730674 | 0.98 | CA1 (0.43) | CA1CA2CA4TP53 | |
| SCHEMBL31376174 | 0.87 | GBA1 (0.31) | CA1CA2CA4 | |
| SCHEMBL1132729 | 0.82 | CA1 (0.43) | CA1CA2CA4TP53SMN1; SMN2 | |
| SCHEMBL12676495 | 0.78 | CA1 (0.38) | CA1CA2CA4TP53SHBG | |
| SCHEMBL12676494 | 0.78 | CA1 (0.38) | CA1CA2CA4TP53SHBG | |
| SCHEMBL12676496 | 0.78 | CA1 (0.38) | CA1CA2CA4TP53SHBG | |
| SCHEMBL18638209 | 0.77 | CA1 (0.43) | CA1CA2CA4SMN1; SMN2 | |
| SCHEMBL12069650 | 0.77 | CA1 (0.43) | CA1CA2CA4SMN1; SMN2 | |
| SCHEMBL18543676 | 0.76 | CA1 (0.39) | CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040091515-A1 | Noxious-insect repellent | KANEBO, LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6686396-B2 | NO OFFENSIVE ODOR AND EXHIBIT EXCELLENT NOXIOUS-INSECT REPELLING EFFECT AND DURABILITY | KANEBO, LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-6677384-B1 | CARBOCYCLIC ALCOHOLS SUCH AS 2-HYDROXYMETHYL-3,3,5-TRIMETHYL-CYCLOHEXANOL USED AS ODORLESS, DURABLE LOTIONS TO PREVENT DISEASES | KANEBO, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143070-A1 | Noxious-insect repellent | KANEBO, LTD. | 2002-10-03 | — | — | US | disclosed |
| US-6372804-B1 | HYDROXYALKYLCYCLOALKANOLS REPELLENTS | KANEBO, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6130255-A | EXPOSING NOXIOUS INSECTS TO REPELLENT COMPRISING 2-(1-HYDROXYALKYL)-CYCLOALKANOLS HAVING NO OFFENSIVE ODOR | KAO CORPORATION (JP) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143070-A1 | Noxious-insect repellent | OPRM1, OPRD1, L3MBTL1 | CA1 4038/4885CA2 3608/4885CA4 4745/4885 |
| US-20040091515-A1 | Noxious-insect repellent | OPRM1, OPRD1, OPRK1 | CA1 4042/4885CA2 3942/4885CA4 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.